New technology may be applicable to other autoimmune diseases and allergies
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
After treatment with the technology, the patients were able to eat gluten with a substantial reduction in inflammation. The results also show a trend toward protecting patients’ small intestine from gluten exposure.
The findings will be presented as a late-breaking presentation Oct. 22 at the European Gastroenterology Week conference in Barcelona, Spain.
The technology is a biodegradable nanoparticle containing gluten that teaches the immune system the antigen (allergen) is safe. Thenanoparticle acts like a Trojan horse, hiding the allergen in a friendly shell, to convince the immune system not to attack it.
Beyond celiac disease, the finding sets the stage for the technology — a nanoparticle containing the antigen triggering the allergy or autoimmune disease — to treat a host of other diseases and allergies including multiple sclerosis, type 1 diabetes, peanut allergy, asthma and more.
The technology was developed in the lab of Stephen Miller, professor of microbiology and immunology at Northwestern University Feinberg School of Medicine, who has spent decades refining the technology.
“This is the first demonstration the technology works in patients,” said Miller, the Judy Gugenheim Research Professor of Microbiology and Immunology.“We have also shown that we can encapsulate myelin into the nanoparticle to induce tolerance to that substance in multiple sclerosis models, or put a protein from pancreatic beta cells to induce tolerance to insulin in type 1 diabetes models.”
When the allergen-loaded nanoparticle is injected into the bloodstream, the immune system isn’t concerned with it, because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell that clears cellular debris and pathogens from the body.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. “The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.”
In the celiac disease trial, the nanoparticle was loaded with gliadin, the major component of dietary gluten, found in cereal grains such as wheat. A week after treatment, the patients were fed gluten for 14 days. Without treatment, celiac patients eating gluten developed marked immune responses to gliadin and damage in their small intestine. Celiac patients treated with the COUR nanoparticle, CNP-101, showed 90% less immune inflammation response than untreated patients. By stopping the inflammatory response, CNP-101 showed the capacity to protect the intestines from gluten related injury.
There currently is no treatment for celiac disease.
“Doctors can only prescribe gluten avoidance, which is not always effective and carries a heavy social and economic toll for celiac patients,” Miller said.
About 1% of the population has celiac disease,a serious autoimmune disease in which the ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten (a protein found in wheat), their body mounts an immune response that attacks the small intestine.
Autoimmune diseases generally can only be treated with immune suppressants that provide some relief, but undermine the immune system and lead to toxic side-effects. CNP-101 does not suppress the immune system but reverses the course of disease.
“Celiac disease is unlike many other autoimmune disorders because the offending antigen (environmental trigger) is well known — gluten in the diet,” said Dr. Ciaran Kelly, professor of medicine at Harvard Medical School and director of the Celiac Center at Beth Israel Deaconess Medical Center. “This makes celiac disease a perfect condition to address using this exciting nanoparticle induced immune tolerance approach.”
Kelly, who will be presenting the research abstract in Barcelona, has been working with Miller to apply the technology and define the therapeutic approach to treating celiac disease.
The nanotechnology was licensed to COUR Pharmaceuticals Co., a biotech based in Northbrook and co-founded by Miller. COUR developed CNP-101, which was granted Fast Track status from the U.S. Food and Drug Administration, and brought the therapy to patients in collaboration with Takeda Pharmaceuticals. Takeda will announce Tuesday they have acquired an exclusive global license to develop and commercialize this investigational medicine for celiac disease.
“Given the license by Takeda, COUR will focus on clinical programs in peanut allergy and multiple sclerosis in the near term and broaden even further over time,” said John J. Puisis, president and chief executive officer of COUR.
Learn more: New treatment may reverse celiac disease
The Latest on: Celiac disease
via Google News
The Latest on: Celiac disease
- Can Celiac Disease Affect Your Weight Loss?on September 16, 2022 at 5:08 pm
It is not uncommon for people with celiac disease to gain weight at some point. Because of this, many people think that celiac disease causes weight gain, but this isn't necessarily the case. Because ...
- La. company puts rice back on the menu for people with diabetes, celiac, hypertensionon September 15, 2022 at 9:43 pm
Low-glycemic Rice was developed by scientists at the LSU AgCenter to help regulate blood sugar levels at a much steadier pace.
- NIMA Partners and empowerDX, a division of Eurofins, Announce Strategic Partnership to Promote New Celiac Disease Genetic Risk Teston September 15, 2022 at 9:35 am
Home Test, Identifies HLA Genetic Risk Factors for Celiac Disease with >99% Accuracy NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles, ...
- Understanding celiac disease: Learn these 5 factson September 15, 2022 at 7:00 am
For millions of Americans living with celiac disease, eating gluten (a protein found in wheat, barley and rye) can be a big problem. That’s because celiac disease leads to ...
- Health and Mind: Celiac Disease Awareness Day is September 13on September 13, 2022 at 12:00 pm
By Amy Williams MS, RD, LD Celiac Disease Awareness Day is September 13th. Celiac disease is known as an abnormal immune system response that damages the intestines. Symptoms can vary widely from ...
- National Celiac Disease Awareness Day; here’s what to knowon September 13, 2022 at 10:45 am
Today is National Celiac Disease Awareness Day. You might know about the autoimmune disorder or know someone who has it, but unless you struggle with the symptoms, it might be hard to ...
- 73% of Celiac Disease Patients Still Exposed to Gluten Every Year, Highlighting Need for a Cure on National Celiac Disease Awareness Dayon September 13, 2022 at 6:11 am
The only current celiac disease treatment, which is only partially effective, is to follow a strict, gluten-free diet. However, the survey of 1,255 Americans who have been diagnosed with celiac ...
- National Celiac Disease Awareness Day: Important Facts To Know About The Autoimmune Disorderon September 13, 2022 at 4:14 am
National Celiac Disease Awareness Day is observed every Sept. 13 as it marks the birthday of Dr. Samuel Gee, who in 1888 described celiac disease as "a kind of chronic indigestion which is met within ...
- Tuesday is National Celiac Disease Awareness Dayon September 12, 2022 at 5:30 pm
Each year, September 13 is marked as National Celiac Disease Awareness Day. The purpose of the day is to raise awareness and garner support for individuals ...
- Healthier Together: Understanding Celiac Diseaseon September 12, 2022 at 10:19 am
While we may be more aware than ever of the impact gluten has on many people’s health, celiac disease is still dramatically under diagnosed.
via Bing News